The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Nektar; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Pfizer; Roche Pharma AG
ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).
 
Debu Tripathy
Consulting or Advisory Role - Nektar; Novartis; Pfizer; Puma Biotechnology
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; Genentech; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
Research Funding - Bristol-Myers Squibb; Eisai; Eisai; Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Andrew David Seidman
Honoraria - Eisai; Genentech; Genomic Health; Novartis
Consulting or Advisory Role - Eisai; Nektar
Speakers' Bureau - Eisai; Genentech; Genomic Health; Novartis
Research Funding - Bayer; Novartis
 
Carey K. Anders
Consulting or Advisory Role - Angiochem; Genentech/Roche; Kadmon; Lilly; Merrimack; Nektar; Novartis; Sanofi; to-BBB technologies BV
Research Funding - Angiochem (Inst); Cascadian Therapeutics (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tesaro (Inst); to-BBB technologies BV (Inst)
Patents, Royalties, Other Intellectual Property - Jones and Bartlell; Up to Date.com
 
Nuhad K. Ibrahim
Honoraria - Celgene; Novartis; Roche
Speakers' Bureau - Celgene; Novartis; Roche
Research Funding - Archer (Inst); GenomeDx (Inst); Newlink Genetics (Inst)
Travel, Accommodations, Expenses - Novartis; Roche
 
Hope S. Rugo
Honoraria - Genomic Health
Consulting or Advisory Role - Amgen
Speakers' Bureau - Genomic Health
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Immunomedics (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech
 
Chris Twelves
Honoraria - Daiichi Sankyo; Eisai; Nektar
 
Véronique Diéras
Consulting or Advisory Role - Abbvie; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Volkmar Mueller
No Relationships to Disclose
 
Alison Hannah
Leadership - NeoGenomics Laboratories
Stock and Other Ownership Interests - NeoGenomics Laboratories
Consulting or Advisory Role - BeiGene; Nektar; Pfizer
 
Mary Ann Tagliaferri
Employment - Nektar
Leadership - Nektar
Stock and Other Ownership Interests - Nektar
Consulting or Advisory Role - Bluebird Bio (I); Nektar (I)
Patents, Royalties, Other Intellectual Property - Nektar
Travel, Accommodations, Expenses - Bluebird Bio (I); Nektar; Nektar (I)
 
Javier Cortés
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Roche